Biological and medicinal significance of pyrimidines

Current Science

Volumn 90, Issue 6, 2006, Pages 793-803

  Jain, K S ^a   Chitre, T S ^a   Miniyar, P B ^a   Kathiravan, M K ^b   Bendre, V S ^a   Veer, V S ^b   Shahane, S R ^a   Shishoo, C J ^c  

^a SINHGAD COLLEGE OF PHARMACY   (India)

^b BHARATI VIDYAPEETH DEEMED UNIVERSITY   (India)

^c L M COLLEGE OF PHARMACY   (India)

Author keywords

Heterocycles; Pyrimidines: biological significance; Pyrimidines: medicinal significance

Indexed keywords

EID: 33645717908     PISSN: 00113891     EISSN: 00113891     Source Type: Journal    
DOI: None     Document Type: Review

References (93)

1. Eussell, J. A., Annu. Rev. Biochem., 1945, 14, 309.
2. Cox, R. A., Quart. Rev., 1968, 22, 499.
3. Cox, R. A., Quart. Rev., 1968, 22, 934.
4. Callery, P. and Gannett, P., Cancer and cancer chemotherapy. In Foye's Principles of Medicinal Chemistry (eds Williams, D. A. and Lemke, T. L.), Lippincott Williams and Wilkins, Philadelphia, 2002, pp. 934-935.
5. Al Safarjalani, O. N., Zhou, X. J., Ras, R. H., Shi, J., Schinazi, R. F., Naguib, F. N. and El Kouni, M. H., Cancer Chemother. Pharmacol., 2005, 55, 541-551.
6. Remers, W. A., Antineoplastic agents. In Wilson and Gisvold's Textbook of Organic Medicinal and Pharmaceutical Chemistry (eds Delgado, J. N. and Remers, W. A.), Lippincott Williams and Wilkins, Philadelphia, 1998, pp. 366-368.
7. Elion, G. B., Fed. Proc., 1967, 26, 898.
8. Burchenal, J. H. et al., Blood, 1953, 8, 965.
9. Clarkson, B. D., Cancer, 1970, 5, 227.
10. Giller, S. A., Zhuk, R. A. and Lidak, M. I. U., Dokl. Akad. Nauk. SSR, 1967, 176, 332.
11. Ambrus, J. L., Stadler, I., Kulaylat, M., Koreshi, A. and Akhtar, S., J. Med. Chem., 1996, 27, 21-31.
12. Weller, M., Muller, B., Koch, R., Bamberg, M. and Krauseneck, P., J. Clin. Oncol., 2003, 21, 3276-3284.
13. Horton, T. M. et al., Clin. Cancer Res., 2005, 11, 1884-1889.
14. Kennedy, B. J., Torkelson, J. L. and Torlakovic, E., Cancer, 1999, 85, 2265-2272.
15. Bertino, J. R. et al., Biochem. Pharmacol., 1979, 28, 1983.
16. Chris, H. T., The Oncologist, 1996, 1, 68-81.
17. Hertel, L. W., Border, G. B., Kroin, J. S., Rinzel, S. M., Poore, G. A., Todd, G. C. and Grindey, G. B., Cancer Res., 1990, 50, 4417-4422.
18. Cheng, C. C. and Roth, B., In Progress in Medicinal Chemistry (eds Ellis, G. P. and West, G. B.), Butterworths, London, 1971, vol. 8, p. 61.
19. Hitchings, G. H., Elion, G. B., Wanderers, H. and Falco, E. A., J. Biol. Chem., 1948, 174, 765.
20. Futterman, S., J. Biol. Chem., 1957, 228, 1031.
21. Werkheiser, W. C., J. Biol. Chem., 1961, 236, 888.
22. Cheng, C. C. and Roth, B., In Progress in Medicinal Chemistry (eds Ellis, G. P. and West, G. B.), Butterworths, London, 1982, vol. 19, p. 267.
23. Montgomery, J. A., Johnston, T. P. and Shealy, Y. F., In Burgers Medicinal Chemistry, Part II (ed. Wolf, M. E.), Wiley-Interscience, New York, 1979, p. 595.
24. Kompis, I. and Wick, A., Helv. Chim. Acta, 1977, 60, 3025.
25. Shinogi, US Patent, 2 888 455, 1959.
26. MacDonald, L. and Kazanijan, P., Formulary, 1996, 31, 470.
27. White, N. J., N. Engl. J. Med., 1996, 335, 800.
28. Von Zabern, I., Nolte, R., Przyklenk, H. and Vogt, W., Int. Arch. Allergy Appl. Immunol., 1985, 76, 205-213.
29. Huges, J., Roberts, L. C. and Coppridge, A. J., J. Urol., 1975, 114, 912-914.
30. Kwee, M. S. L. and Stolk, L. M. L., Pharm. Weekbl. (Sci.), 1984, 6, 101-104.
31. Mitsuya, H. et al., Proc. Natl. Acad. Sci. USA, 1985, 82, 7096.
32. Mansuri, M. M. and Martin, J. C., Annu. Rep. Med. Chem., 1987, 22, 147.
33. Sullivan, V., Talarico, C. L., Stanat, S. C., Davis, M., Coen, D. M. and Biron, K. K., Nature, 1992, 358, 162.
34. Johnson, M. A., Verpooten, G. A., Daniel, M. J., Plumb, R., Moss, J., Van Caesbroeck, D. and De Broe, M. E., Br. J. Clin. Pharmacol., 1998, 46, 21-27.
35. Van Leeuwen, R., J. Infect. Dis., 1995, 171, 1161.
36. Mitsuya, H. (ed.), Anti-HIV Nucleosides: Past, Present and Future, Chapman and Hall, New York, 1997.
37. Gorbach, S. L., Barlett, J. G. and Blacklow, N. R., Infectious Diseases, Saunders and Company, Philadelphia, 1998, pp. 330-350; 1154-1168.
38. Reddick, J. J., Saha, S., Lee, J., Melnick, J. S., Perkins, J. and Begley, T. P., Bioorg. Med. Chem. Lett., 2001, 11, 2245-2248.
39. Singh, P., Kumar, R. and Sharma, B. K., J. Enzyme Inhib. Med. Chem., 2003, 18, 395-402.
40. Wakelin, L. P. G. and Waring, M. J., DNA intercalating agents. In Comprehensive Medicinal Chemistry, Drug Compendium (ed. Sammers, P. G.), Pergamon Press, 1990, vol. 2, p. 731.
41. Polak, A. and Scholer, H. J., Chemotherapy, 1975, 21, 113.
42. Hunter, P. A., Darby, K. G. and Russel, N. J., Fifty years of antimicrobials: Past perspectives and future trends. In Symposia of the society for General Microbiology (ed. Collins, M.), Cambridge University Press, Cambridge, 1995.
43. Chadwick, B., Addy, M. and Walker, D. M., Br. Dent. J., 1991, 71, 83-86.
44. Hunziker, F., Helv. Chim. Acta, 1967, 50, 1588.
45. Nomoto, S., J. Antibiot., 1977, 30, 955.
46. Gale, E. F., Cundliffe, E., Reynolds, P. E., Richmond, M. H. and Waring, M. J., The Molecular Basis of Antibiotic Action, Wiley and Sons, 1981, 2nd edn, pp. 500-502.
47. Daniels, T. C. and Jorgensen, E. C., Central nervous system depressants. In Wilson and Gisvold's Textbook of Organic Medicinal and Pharmaceutical Chemistry (ed. Doerge, R. F.), J. B. Lippincott, Philadelphia, 1982, p. 33.
48. Furukawa, S. et al., J. Vet. Med. Sci., 2000, 62, 23-28.
49. Threlkeld, D. S., Facts and Comparisons, 1998, pp. 269g-280a.
50. Vida, J. and Yevich, J., Sedative hypnotics. In Burger's Medicinal Chemistry and Drug Discover (ed. Abrahim, D. J.), John Wiley, New Jersy, 2003, vol. 6, 6th edn, pp. 203-205.
51. Eli Lilly, US Patent, 1 856 792, 1932.
52. Taylor, D. P., Allen, L. E., Becker, J. A., Crane, M., Hyslop, D. K. and Riblet, L. A., Drug Rev. Res., 1984, 4, 95.
53. Temple, D. L., Yevich Jr. J. P. and Now, J. S., J. Clin. Psychiatry, 1982, 43, 4.
54. Peroutka, S. S., Biol. Psychiatry, 1985, 20, 971.
55. Coalpaert, F. C., Meert, T. F., Niemegens, C. J. E. and Janssen, P. A. J., Psychopharmacology, 1985, 86, 45.
56. Fur, G., Le Burgerin, M. C., Malgoures, C. and Uzan, A., Neuropharmacology, 1979, 18, 591.
57. Howard, H. R. and Seeger, T. F., Annu. Rep. Med. Chem., 1993, 28, 39.
58. Abott, US Patent, 2 153 729, 1939.
59. Abott, US Patent, 2 153 729, 1934.
60. Arnaud, M. J., Products of metabolism of caffein. In Caffein, Perspectives from Recent Research (ed. Dews, P. B.), Springer-Verlag, New York, 1984, p. 3.
61. Klosa, J., Arch. Pharm. Ber. Dtsch. Pharm. Ges, 1955, 288, 301.
62. Chemische Werke Albert, DOS, 1973, 2 330 741.
63. Gane's Chem. Works, US Patent, 2 715 125, 1955.
64. Degussa, DE, 1 119 868, 1959.
65. Wallace and Tiernan, US Patent, 3 360 518, 1967.
66. Spickett, R. G. W. and Timmis, G. M., J. Chem. Soc., 1954, 2887.
67. Pfizer, US Patent, 3 511 836, 1970.
68. Koshy, M. M. and Mickey, D., Circulation, 1977, 55, 533.
69. Hara, H., Ichikawa, M., Oku, H., Shimazawa, M. and Araie, M., Cardiovasc. Drug Rev., 2005, 23, 43-56.
70. Honkanen, E., Pipuri, A., Kairisalo, P., Nore, P., Karppaness, H. and Paakari, I., J. Med. Chem., 1983, 26, 143.
71. Meredith, P. A., Scott, P. J., Kelman, A. W., Hughes, D. M. and Reid, J. L., Am. J. Ther., 1995, 2, 541-545.
72. Ganzevoort, W., Rep, A., Bonsel, G. J., de Vries, J. I. and Wolf, H., Hypertension, 2004, 22, 1235-1242.
73. Wong, W. M., Ann. Pharmacother., 1994, 28, 290-291.
74. Jargon, A., Lancet, 1991, 337, 1457-1459.
75. Langtry, H. D., Drugs, 1989, 38, 900-940.
76. Reynolds, J. E. F. (ed.), Martindale, The Extra Pharmacopoeia, Council of The Royal Pharmaceutical Society of Great Britain, London, 1996, 31st edn, p. 926.
77. Wulfing, J. A., US Patent, 2 924 598, 1960.
78. Debarge, J., FE-M, 828, 1960.
79. Engel, J., Granerus, A. K. and Svanborg, A., Eur. J. Clin. Pharmacol., 1975, 8, 223-226.
80. Reynolds, J. E. F. (ed.), Martindale, The Extra Pharmacopoeia, Council of The Royal Pharmaceutical Society of Great Britain, London, 1996, 31st edn, pp. 1651-1652.
81. Gane's ChemWorks, US Patent, 2715 125, 1955.
82. Brown, E. A., Griffith, R., Harvey, C. A. and Owen, D. D. A., Brit. J. Pharmacol., 1986, 87, 569.
83. Ganellin, C. R. et al., Engl. Reg. Allergy Proc., 1986, 7, 126.
84. Bristol-Myer, US Patent, 4 122 274, 1978.
85. Promonta, DE, 934 890, 1951.
86. Gauthier, B., Ann. Pharm. Fr., 1963, 21, 655.
87. Takeda, US Patent, 3 016 380, 1962.
88. Tani, J., J. Med. Chem., 1979, 22, 95.
89. Vanderhaeghe, H. and Claesen, M., Bull. Chim. Belg., 1959, 68, 30.
90. Schlenk, Enzymologia, 1965, 29, 283.
91. Fujisawa, US Patent, 3 098 856, 1963.
92. Clissold, S. P. and Beresford, R., Drugs, 1984, 33, 478-502.
93. Jones, M. E., Annu. Rev. Biochem., 1980, 49, 233-279.